Gilead Sciences Inc. GILD has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.
The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.
Also Read: Gilead Unveils ‘Remarkable Outcomes’ From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections.
The affected product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air mail, instructing pharmacies to cease use of the affected lot and return any remaining vials.
Gilead is taking necessary measures to ensure the safety of patients and healthcare providers by facilitating the recall process.
The administration of a contaminated injectable could lead to health risks, including local irritation or swelling. If glass particles travel through the bloodstream, they may obstruct blood vessels in vital organs, potentially resulting in strokes or even death.
Gilead has reported no adverse events associated with this recall to date.
Veklury is designed for the treatment of COVID-19 in both adults and pediatric patients, specifically those who are hospitalized or non-hospitalized but at high risk of progression to severe COVID-19.
Its use is restricted to healthcare settings that manage severe reactions, including anaphylaxis.
In 2021, Gilead Sciences issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because they contained glass particulates.
In the second quarter of 2024, Veklury sales decreased 16% year over year to $214 million, primarily due to lower rates of COVID-19-related hospitalizations.
Price Action: GILD stock is down 0.05% at $83.90 at last check Monday.
Image via Unsplash
Read Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
